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Two brothers with congenitally-acquired Chagas’ disease (CD) diagnosed during adulthood are reported.
The patients were born in the USA to a mother from Boliviawho on subsequent assessment was found to
be serologically positive for Trypanosoma cruzi. Serologic screening of all pregnant womenwhomigrated
from countries with endemic CD is strongly recommended.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
American trypanosomiasis, a chronic systemic parasitosis also
known as Chagas’ disease (CD), is caused by the protozoan
kinetoplastid parasite Trypanosoma cruzi. CD has afﬂicted humani-
ty since its earliest presence in the New World and is still the
largest parasitic disease burden of the American continent. The
disease is technically a zoonosis, as the natural reservoirs of the
T. cruzi are a large variety of marsupial and placental mammals
autochthonous to the American continent, the parasite being
naturally transmitted among them by Reduviid (Triatominae)
hematophagous insects. Human disease results from the invasion
of natural ecotopes, as well as from the establishment of the
vectors in human dwellings, due to the poor socioeconomic
conditions of most rural human populations from Mexico to
Argentina, where the disease is endemic. Vector-borne transmis-
sion to humans initiates when the infected Triatomine bug
defecates after a blood meal. The metacyclic trypomastigotes
present in fecal droplets enter through the bite wound or by direct
contact with mucosal membranes causing infection. The parasite
can also be transmitted congenitally from infected mothers to
newborns, by transfusion of contaminated blood, organ trans-
plants and orally by ingestion of contaminated foods and drinks.
These routes of transmission, together with intense international
migrations in recent decades, have led to the spread of the disease
to non-endemic areas, such as the U.S., Western Europe, Australia
and Japan [1].
According to World Health Organization, in 2015, about
6–7 million people are estimated to be infected with T. cruzi
worldwide and responsible for 12,000 deaths annually, mostly in
21 endemic Latin American countries [2]. Three countries,
Argentina, Brazil and Mexico, concentrate more than 60% of cases,
followed by Bolivia and Colombia [2]. In the US it has been
estimated that 2% of approximately 17 million Latin American
immigrants in 2007, were potentially infected with T. cruzi; of
these, approximately 65,000 might have or may develop signs and
symptoms of chronic CD [3]. It is estimated that between 63 and
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315 acquire T. cruzi infection in the U.S every year. Based on these
estimates, Chagas cardiomyopathy may affect approximately
30,000–45,000 persons in the United States [4,5]. According to
the Pan American Health Organization (PAHO), congenital
transmission appears to account for more than 25% of the world
new cases of CD [6]. In the United States there is great concern for
potential congenital transmission of T. cruzi from infected mothers
to infants [7]. Theﬁrst documented case of congenital transmission
in the United States was recorded in 2012 [8]. The patient was born
by cesarean section at 29 weeks of gestational age due to fetal
hydrops from an asymptomatic mother with history of Chagas
disease diagnosed in Bolivia (country of origin), but never treated
for the infection [8].
We report two adult male siblings with presumptive congenital
transmission of T. cruzi, born in the United States to a Bolivian
seropositivemother, who had a strong epidemiological exposure to
triatomine insects 28 years prior to her migration to the United
States.
Case reports
Case 1: A 24-year-old Hispanic male was referred by the
Florida Health Department for evaluation after a voluntary blood
donation serology for CD tested positive in September 2014. The
patient was born and raised in the state of Maryland (Silver
Spring) and at the age of 5 moved to Miami, Florida. The patient
had no exposure to potential sources of infected vectors, such as
sub-standard housing (i.e. cracks on the walls and foundations of
homes made of adobe/mud, thatched roofs) and/or potential
animal reservoirs and infected vectors, either in the United States
or during his four visits, for less than two weeks each, to La Paz
city in Bolivia. An interview with the patient’s mother revealed
that during his childhood, the patient never visited or stayed in
high endemic rural areas for CD in Bolivia. Past medical history: In
May 2013, the patient was evaluated for left sided chest pain in
the emergency department of one of the local hospitals. His
physical examination and laboratory results were normal,
including cardiac enzymes. An electrocardiogram (EKG) was
obtained and reported as normal. Seven months later, an
outpatient follow up evaluation showed no symptoms and his
general physical examination was normal. Laboratory work
showed a normal blood cell count, chemistry (BUN, creatinine,
electrolytes), and liver function tests (ALT, AST). A repeated
serology for T. cruzi antibodies was reactive. The patient never
received a blood transfusion and reported a non-complicated
dental surgery. In February 2015, a new EKG revealed an
incomplete right bundle branch block (RBBB) and ﬁrst-degree
atrioventricular (AV) block (Fig. 1). A transthoracic echocardio-
gramwas normal. T. cruzi serology was conﬁrmed by two different
serology tests. A T. cruzi enzyme immunoassay (AB EIA), was
reactive: OD 2.747 (reactivity: OD>0.330; Sens. 100%, Spec. 98.7%).
An immunoblot assay AB IB (TESA), was reported positive (Sens.
97.6%, Spec. 96.6%). Both tests were performed at the Center for
Disease Control and Prevention (CDC). The patient was treated
orally with Nifurtimox at 10mg/kg, daily, divided in three doses,
for 90 days. The patient completed the treatment and only
reported loss of appetite and weight during drug administration.
Follow up laboratory work (complete blood count, basic chemistry
analysis and liver function tests) was normal.
Case 2: As a result of an extended epidemiological family
questioning analysis, the patient’s only sibling was contacted for
evaluation. The patient is a 26 year-oldmale, whowas diagnosed to
have a positive serology for T. cruzi in 2008 post a voluntary blood
donation, and conﬁrmed by the CDC. The patient denied previous
blood transfusions and never traveled to Bolivia or any other
endemic destinations in the Americas. In 2012, a new evaluation
and EKG were normal. Treatment with Nifurtimox, 10mg/kg orally
daily, divided in three doses for 90days as per CDC protocol, was
provided. The patient tolerated and completed treatment. His
primary care physician has followed him on a regular basis, and to
date the patient has remained without evidence of active clinical
disease.
The patients’ mother was born and resided in the city of
Concepción, Bolivia, until she was 18 years of age. She lived in a
house described with mudwalls and thatch. She had knowledge of
the existence of the triatomine insects locally called “vinchuca”.
She moved to Silver Spring, Maryland in 1982 where she had two
uneventful pregnancies and deliveries in 1988 and 1990,moving to
Miami ﬁve years later.While in the United States, themother never
lived in sub-standard housing, rural or sub-urban areas, had
contact with potential animal reservoirs, or received blood
transfusions. She had been a blood donor prior to the Red-Cross
protocol including Chagas’ disease screening since 2007 [5].
Considering that the two sons were diagnosed with CD without a
clear known source of infection, shewas tested at the blood bank as
per her sons’ request. The initial blood bank serology was positive
(March 2011) and most recently conﬁrmed by the CDC in April
2015. Treatment was offered to the patient, but she never returned
for follow up.
Discussion
The present report represents the second instance of congenital
transmission in the United States. Congenital transmission varies
among study population and parasite load [9]. The capacity of
parasites to invade placental cells, as well as its virulence and level
of parasitemia in pregnant women, is critical in the maternal-fetal
transmission. Parasitemia increases during the 2nd and 3rd
trimesters of pregnancy and high maternal parasitemia are
associated with congenital transmission. Indeed, transmission
occurs in nearly 100% of pregnant women with reactivated
infections, in about 50% of acute infection during pregnancy,
and in roughly 5% of chronic infection in endemic countries [14,15].
Autochthonous infections have been reported in the United States.
The CDC has conﬁrmed twenty-eight cases have been locally
transmitted from 1955 to 2015 [10]. Vector human transmission in
the United States is rare and is likely related to a lower vector
transmission efﬁcacy due to the delayed defecation of the
triatomine insects and better housing conditions [39_TD$DIFF] 11,12]. Although
possible, vectorial transmission in our cases is extremely unlikely
in view to the fact that the patients never lived in sub-standard
conditions in the United States or were exposed to vectors and
small animal reservoirs while traveling (La Paz city, Bolivia, case 1).
Patients were born to an infected mother who was never screened
for CD during her two pregnancies, despite a strong epidemiologi-
cal history of exposure toT. cruzi in Bolivia. The epidemiology of CD
is changing due to immigration from endemic areas of Latin
America. Around 300,000 persons infected with T. cruzi are
estimated to live in the United States [6]. The National Notiﬁable
Disease Surveillance System (NNDSS) of the United States does not
require the mandatory notiﬁcation of CD to public health
authorities, making it difﬁcult to accurately evaluate local
transmission. Few states (Massachusetts, Arizona, Texas and
Tennessee) consider CD a notiﬁable disease. Public entities at
the Federal and State level need to support the expansion of the
surveillance programs nationwide. Awareness of CD among
physicians in the United States – in particular primary care
physicians, pediatricians, obstetricians and cardiologists – is fairly
low [6]. The limited knowledge of congenital T. cruzi transmission
is reﬂected by the lack of screening of pregnant women at risk, as
evidenced in the current report.
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The identiﬁcation of T. cruzi by xenodiagnosis CD and can be
routinely used to accurately diagnose the disease in the acute
phase. However, during the indeterminate or chronic phase,
diagnosis is made by serological methods.
Once a positive diagnosis has been conﬁrmed, there are only
two drugs available for treatment (nifurtimox and benznidazole).
Nifurtimox (Lampit1, Bayer; a 2-nitrofuran) is the only anti-T. cruzi
agent available in the US, through CDC. The drug, as well as
benznidazole (LAFEPE; a 5-nitroimidazole available in Latin
America), is active in acute infections (80–95%), and efﬁcacy
varies among the endemic areas probably due to differences in the
in vivo susceptibility of the circulating parasite populations.
[(Fig._1)TD$FIG]
Fig. 1. Incomplete right bundle branch block (RBBB) and ﬁrst-degree atrioventricular (AV) block.
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Congenital CD response to treatment is close to a 100% cure and
generally well tolerated when treatment is administered within
the ﬁrst year of life [13–15]. The efﬁcacy of both drugs in the
prevalent chronic phase of the disease is signiﬁcantly lower and
more variable, depending on the duration of the infection [16]. Two
recent studies that evaluated the efﬁcacy of nifurtimox in chronic
patients using quantitative T. cruzi PCR and a novel proteomic
biomarker found that in 77.8% and 43.3% of treated patients the
circulating parasite burden dropped below the limit of detection of
the methods after 13 and 36 months, respectively [17,18]. Adverse
effects are frequent, dose-related and reversible: they include
anorexia, nausea, vomiting, gastric pain, insomnia, headache,
vertigo, excitability, myalgia, arthralgia and convulsions; periph-
eral polyneuritis can occur which may necessitate discontinuation
of treatment [19].
The diagnosis and treatment of CD needs to be emphasized and
should be included in routine laboratory tests of pregnancy among
immigrant women from endemic countries. All infants with
congenital disease should be treated during the ﬁrst twelve
months due to the high cure rates and treatment tolerance.
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